Monday, March 09, 2015 3:45:59 PM
Food and Healthcare Likely to Carry 2015
Several collaborators will advance human therapeutics into
clinical trials this year. Overall, Intrexon figures that about 10
products developed with its assistance will be in testing. Ziopharm
alone will likely account for at least half of them and two other
companies, Fibrocell Science and Synthetic Biologics, will have
one each. Another therapy that was mentioned was developed as
part of the Sun Pharma joint venture in ophthalmology. Recently
acquired ActoGenix has two clinical-stage programs involving
genetically modified bacteria for oral mucositis and inflammatory
bowel disease, which will probably be partnered soon.
A pending acquisition will expand Intrexon’s presence in
the food sector… The Company has agreed to pay $41 million
for Okanagan Specialty Fruits, including $10 million in cash and
the remainder in XON stock. The deal, which should close by
June, will bring two approved, non-browning apple varieties into
the product line and add three similar genetically modified fruit
programs to the R&D pipeline. Note that we do not expect
revenues from Okanagan until 2017.
…while Trans Ova should drive revenues this year. This
subsidiary, which was acquired last August, will likely generate
close to $100 million in revenue from its dairy and cattle
embryo sales and in vitro fertilization services. Demand, which
is seasonally strongest in the June quarter, is growing at a rapid
pace.
Intrexon closed 2014 on a pleasant note. Fourth-quarter
revenues benefited from $15.1 million in sales and service
revenues from Trans Ova in its first full quarter with the
Company. The other major contributor was $13 million in
collaboration revenues. Operating expenses were generally in
line with expectations. The profit margin on product and service
revenues, which were generated largely by Trans Ova, amounted
to 29% during the seasonally weak December interim. R&D costs
increased 41%, to $59 million, while selling and administrative
expenses jumped 61%, to $64 million, due largely to acquisitions.
Overall, the operating loss increased modestly from year-toyear,
to $19 million. More than offsetting that was unrealized
appreciation in stocks of the Company’s collaborators, which
resulted in a $0.19-a-share profit in the quarter.
We are maintaining our BUY recommendation on Intrexon
shares and our $65 price target.
http://www.griffinsecurities.com/viewpdf.php?docid=959
I Love you cause you Hate me
Recent PGEN News
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting • PR Newswire (US) • 05/23/2024 09:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:23:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:19:47 PM
- Precigen Reports First Quarter 2024 Financial Results and Business Updates • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting • PR Newswire (US) • 05/08/2024 08:05:00 PM
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting • PR Newswire (US) • 04/24/2024 02:20:00 PM
- Actym Therapeutics Appoints Thomas Smart as CEO • PR Newswire (US) • 04/24/2024 01:00:00 PM
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Precigen Reports Full Year 2023 Financial Results and Business Updates • PR Newswire (US) • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th • PR Newswire (US) • 03/05/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/27/2024 06:48:40 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:20:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:25:09 PM
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/06/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/18/2024 05:15:14 AM
- Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission • PR Newswire (US) • 01/16/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:39:30 PM
- Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/08/2024 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 10:26:37 PM
- Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 12/18/2023 09:05:00 PM
- Precigen to Participate in the JMP Securities Hematology and Oncology Summit • PR Newswire (US) • 11/29/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:08:34 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM